First Tracks Biotherapeutics, Inc. (TRAX)

First Tracks Biotherapeutics, Inc. is a clinical-stage biotechnology company developing antibody therapies that modulate immune pathways involved in autoimmune and inflammatory diseases. The company was spun off from AnaptysBio in 2026, with AnaptysBio shareholders receiving First Tracks shares, and it began trading on the Nasdaq Global Select Market under the ticker TRAX.

Its lead program is ANB033, an antibody that antagonizes CD122, a component of receptors for cytokines that drive certain immune cells, being studied in celiac disease and eosinophilic esophagitis. The pipeline also includes rosnilimab, a PD-1 agonist antibody designed to deplete and suppress pathogenic T cells, which has been studied in rheumatoid arthritis, and ANB101, an antibody targeting BDCA2 on plasmacytoid dendritic cells.

First Tracks is based in San Diego, California, where its former parent was headquartered.